Monitor for the Lucid-MS Phase 2 IND filing (expected H1 2026 and any updates on the unbuzzd IPO process, which could provide non-dilutive cash via Quantum's 19.84% stake. The ongoing lawsuit against CIBC/RBC for alleged market manipulation remains pending a ruling on motion to dismiss.
Price Chart
Executive Summary
Quantum BioPharma filed a 6-K compiling press releases from March 2025 through August 2026, including its FY2025 audited results showing no going concern, $11.3M cash, reduced operating expenses to $15.3M, and a 50% reduction in payables. The filing also details pipeline progress for Lucid-MS (Phase 1 toxicology complete, IND filing planned H1 2026), unbuzzd's peer-reviewed publication and IPO preparation, and multiple small financings including a convertible debenture offering and debt settlements. Director Terry Lynch resigned. The filing is a routine periodic update with no single material catalyst.
Key Facts
- Cash on hand and digital assets at filing date: $11.3 million USD
- Operating expenses reduced to $15.3M in FY2025 vs $16.1M in FY2024 (-5%)
- Trade and other payables reduced ~50% from $4.1M to $2.0M
- External R&D fees decreased to $2.8M from $6.1M
- G&A expenses decreased to $9.0M from $9.4M
- Lucid-MS Phase 1 oral toxicity studies complete; IND filing for Phase 2 planned H1 2026
- unbuzzd clinical trial published in peer-reviewed journal; unbuzzd hired MNP auditors for possible IPO
- Health Canada granted Product License for Qlarity in Canada
- Director Terry Lynch resigned effective March 27, 2026
- Closed debt settlement of CAD$123,487 via 30,948 Class B shares at CAD$3.99/share
- Granted 572,500 stock options at C$4.80, expiring August 2031
Financial Impact
Cash position of $11.3M provides runway beyond January 2028; operating expenses reduced 5% to $15.3M; payables halved to $2.0M; no revenue or EPS figures reported in the filing
Risk Factors
- Pre-revenue biotech with no approved products; pipeline entirely dependent on Lucid-MS Phase 2 results and regulatory milestones
- Ongoing litigation against CIBC/RBC with uncertain outcome and no material damages stated
- Multiple small dilutive financings (convertible debentures, debt settlements) over the period indicate ongoing cash needs despite $11.3M balance
Investment Themes
Documents Analyzed
This report is based on 14 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001185185-26-004098 |
| Document: qntmex99-2.htm | 0001185185-26-004098 |
| Document: qntm6k091726.htm | 0001185185-26-004098 |
| Document: qntmex99-1.htm | 0001185185-26-004098 |
| Document: qntmex99-3.htm | 0001185185-26-004098 |
| Document: qntmex99-4.htm | 0001185185-26-004098 |
| Document: qntmex99-6.htm | 0001185185-26-004098 |
| Document: qntmex99-7.htm | 0001185185-26-004098 |
| Document: qntmex99-9.htm | 0001185185-26-004098 |
| Document: qntmex99-8.htm | 0001185185-26-004098 |
| Document: qntmex99-10.htm | 0001185185-26-004098 |
| Document: 0001185185-26-004098-index-headers.html | 0001185185-26-004098 |
| Document: 0001185185-26-004098-index.html | 0001185185-26-004098 |
| Document: 0001185185-26-004098.txt | 0001185185-26-004098 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 6-K | $3.11 | awaiting T+20 | — | $2.21 (−28.94%) |
Oct 6, 2026 20d ago | 6-K | $3.09 | awaiting T+20 | — | $2.21 (−28.48%) |
Oct 6, 2026 20d ago | Press Release | $3.09 | awaiting T+20 | — | $2.21 (−28.48%) |
Oct 5, 2026 21d ago | SC 13G/A | $3.27 | awaiting T+20 | — | $2.21 (−32.42%) |
Sep 24, 2026 4w ago | 6-K | $4.00 $2.27 | ▼ −43.25% | ▼ −42.83% | $2.21 (−44.75%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.21 (−40.59%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.21 (−40.59%) |
Sep 15, 2026 5w ago | 6-K | $3.46 $2.89 | ▼ −16.47% | ▼ −19.45% | $2.21 (−36.13%) |
Sep 1, 2026 7w ago | 6-K | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.21 (−28.25%) |
Sep 1, 2026 7w ago | Press Release | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.21 (−28.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers